

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)
(Incorporated in Malaysia)

**Unaudited Condensed Consolidated
Interim Financial Report
for the Second Quarter Ended
31 December 2024**

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

Unaudited condensed consolidated statement of financial position as at 31 December 2024

	Note	Unaudited As at 31 December 2024 RM'000	Audited As at 30 June 2024 RM'000
Assets			
Non-current assets			
Investment in associates		2,639	921
Investment in joint ventures		-	3
Property, plant and equipment	A13	57,811	26,448
Right-of-use assets		3,080	3,753
Deferred tax assets		2,237	1,930
Total non-current assets		65,767	33,055
Current assets			
Inventories		2,250	1,716
Trade receivables		9,953	6,546
Other receivables, deposits and prepayments		1,592	1,588
Fixed deposits with licensed banks		88,206	87,621
Cash and bank balances		6,492	1,917
Total current assets		108,493	99,388
Total assets		174,260	132,443
Equity			
Share capital		87,487	87,487
Reserves		2,357	2,267
Retained profits		25,407	21,543
Total equity		115,251	111,297
Liabilities			
Non-current liability			
Loans and borrowings	B7	25,692	-
Lease liabilities	B8	4,220	5,665
Provision for restoration costs		731	716
Total non-current liability		30,643	6,381

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

Unaudited condensed consolidated statement of financial position as at 31 December 2024 (cont'd)

		Unaudited As at 31 December 2024 RM'000	Audited As at 30 June 2024 RM'000
	Note		
Current liabilities			
Trade payables		7,353	3,669
Other payables and accruals		16,125	7,481
Amount owing to directors		75	154
Lease liabilities	B8	2,730	2,478
Current tax liabilities		2,083	983
Total current liabilities		28,366	14,765
Total liabilities		59,009	21,146
Total equity and liabilities		174,260	132,443

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the financial year ended 30 June 2024 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

Unaudited condensed consolidated statement of profit or loss and other comprehensive income for the second quarter ended 31 December 2024

	Note	← Unaudited →			
		Individual quarter		Cumulative quarter	
		ended 31 December 2024	2023	ended 31 December 2024	2023
		RM'000	RM'000	RM'000	RM'000
Revenue		20,177	16,054	42,466	33,658
Cost of sales		(11,095)	(8,619)	(23,081)	(18,135)
Gross profit		9,082	7,435	19,385	15,523
Other income		1,038	1,187	2,126	2,297
		10,120	8,622	21,511	17,820
Administrative expenses		(6,103)	(4,451)	(11,773)	(8,734)
Other expenses		-	(2)	-	(2)
Finance costs		(88)	(172)	(178)	(347)
Profit from operations		3,929	3,997	9,560	8,737
Share of profit of equity accounted associate		128	-	146	-
Share of profit of equity accounted joint venture		-	-	7	-
Profit before taxation	B12	4,057	3,997	9,713	8,737
Income tax expense	B5	(1,112)	(1,074)	(2,767)	(2,214)
Profit after taxation		2,945	2,923	6,946	6,523
Other comprehensive income		-	-	-	-
Total comprehensive income for the financial period		2,945	2,923	6,946	6,523
Profit after taxation/Total comprehensive income for the financial period attributable to:-					
Owners of the Company		2,945	2,923	6,946	6,523
Earnings per ordinary share (sen)⁽¹⁾					
Basic		0.35	0.35	0.83	0.78
Diluted		0.35	0.35	0.83	0.78

⁽¹⁾ Earnings per ordinary share is calculated based on the weighted average number of ordinary shares referred to in Note B11.

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the Audited Financial Statements for the financial year ended 30 June 2024 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

Unaudited condensed consolidated statement of changes in equity for the second quarter ended 31 December 2024

	Share capital RM'000	Reorganisation reserves RM'000	Long Term Incentive Plan Reserve RM'000	Retained Profits RM'000	Total RM'000
Audited					
At 1 July 2023	87,472	1,530 ⁽¹⁾	477 ⁽²⁾	16,629	106,108
Profit after taxation/total comprehensive income for the financial year	-	-	-	6,523	6,523
Contribution by and distributions to owners of the Company:					
Share options exercised	15	-	(2)	-	13
Share options to executives	-	-	131	-	131
Dividends to owners of the Company	-	-	-	(3,082)	(3,082)
At 31 December 2023	<u>87,487</u>	<u>1,530</u>	<u>606</u>	<u>20,070</u>	<u>109,693</u>

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

Unaudited condensed consolidated statement of changes in equity for the second quarter ended 31 December 2024 (cont'd)

	Share capital RM'000	Reorganisation reserves RM'000	Long Term Incentive Plan Reserve RM'000	Retained profits RM'000	Total RM'000
Unaudited					
At 1 July 2024	87,487	1,530 ⁽¹⁾	737 ⁽²⁾	21,543	111,297
Profit after taxation/total comprehensive income for the financial year	-	-	-	6,946	6,946
Contribution by and distributions to owners of the Company:					
Share options to executives	-	-	90	-	90
Dividends to owners of the Company	-	-	-	(3,082)	(3,082)
At 31 December 2024	<u>87,487</u>	<u>1,530</u>	<u>827</u>	<u>25,407</u>	<u>115,251</u>

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

Unaudited condensed consolidated statement of changes in equity for the second quarter ended 31 December 2024 (cont'd)

(1) The reorganisation reserve represents the difference between the carrying value of the investment and the nominal value of shares of Cengild Sdn Bhd upon consolidation under the pooling-of-interests method of accounting.

(2) The share option reserves arise due to the Executive Share Option Scheme (ESOS) options granted on 15 April 2022.

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the financial year ended 30 June 2024 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

Unaudited condensed consolidated statement of cash flows for the second quarter ended 31 December 2024

	Unaudited Cumulative quarter ended 31 December	
	2024 RM'000	2023 RM'000
Cash flows from operating activities		
Profit before taxation	9,713	8,737
<i>Adjustments for:</i>		
Depreciation of plant and equipment	2,446	891
Depreciation of right-of-use assets	673	652
Rent concessions	(17)	-
Interest expense	160	331
Unwinding of discount	15	15
Plant and equipment written off	-	2
Share options to executives	90	131
Share of net profit of equity accounted associate	(146)	-
Share of net profit of equity accounted joint venture	(7)	-
Interest income	(1,574)	(1,746)
Operating profit before working capital changes	<u>11,353</u>	<u>9,013</u>
Increase in inventories	(534)	(435)
Increase in trade and other receivables	(3,411)	(228)
Increase in trade and other payables	12,328	1,518
Decrease in amount owing to directors	(79)	(73)
Cash generated from operations	<u>19,657</u>	<u>9,795</u>
Tax paid	(1,974)	(1,645)
Interest paid	-	(1)
Net cash from operating activities	<u>17,683</u>	<u>8,149</u>
Cash flows used in investing activities		
Interest income received	1,574	1,746
Investment in an associate	(1,562)	-
Investment in a joint venture	-	(1,275)
Proceeds from disposal of plant and equipment	73	-
Progress payment for property	(31,873)	-
Purchase of plant and equipment	(2,009)	(1,355)
Changes in deposits with tenure more than 3 months	8,869	-
Net cash used in investing activities	<u>(24,928)</u>	<u>(884)</u>

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

Unaudited condensed consolidated statement of cash flows for the second quarter ended 31 December 2024 (cont'd)

	Unaudited Cumulative quarter ended 31 December	
	2024 RM'000	2023 RM'000
Cash flows from/(used) in financing activities		
Dividends paid	(3,082)	(3,082)
Drawdown of term loans	25,692	-
Interest paid	(160)	(330)
Proceeds from exercise of share options	-	13
Repayment of lease liabilities	(1,176)	(658)
Net cash from/(used)used in financing activities	21,274	(4,057)
Net increase in cash and cash equivalents	14,029	3,208
Cash and cash equivalents at the beginning of financial year	23,364	98,308
Cash and cash equivalents at the end of financial year	37,393	101,516

(i) Cash and cash equivalents

Cash and cash equivalents included in the consolidated statement of cash flows comprise the following consolidated statement of financial position amounts:

	Unaudited Cumulative quarter ended 31 December	
	2024 RM'000	2023 RM'000
Cash and bank balances	6,492	1,440
Deposits with financial institution	88,206	100,076
	94,698	101,516
Deposits with tenure more than 3 months	(57,305)	-
	37,393	101,516

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the financial year ended 30 June 2024 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)
(Incorporated in Malaysia)

A. NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT FOR THE SECOND QUARTER ENDED 31 DECEMBER 2024

A1. Basis of preparation

The condensed consolidated interim financial report is unaudited and has been prepared in accordance with the *Malaysian Financial Reporting Standards ("MFRS") 134 Interim Financial Reporting* and Paragraph 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad ("Listing Requirements").

The condensed consolidated interim financial report should be read in conjunction with the Audited Financial Statements for the financial year ended 30 June 2024 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

A2. Significant accounting policies

The accounting policies adopted by the Group in this interim financial report are the same as those applied by the Group in its audited consolidated financial statements for the financial year ended 30 June 2024 except for the adoption of those new Malaysian Financial Reporting Standards ("MFRS") and amendment to MFRS and Interpretations that are applicable to the Group for the financial period beginning 1 July 2024.

(a) As of 1 July 2024, the Group has adopted the following new accounting standards and/or interpretations (including the consequential amendments, if any).

MFRS and/or IC interpretations (including the consequential amendments):

- Amendments to MFRS 16: Lease Liability in a Sale and Leaseback
- Amendments to MFRS 101: Classification of Liabilities as Current or Non-current
- Amendments to MFRS 101: Non-current Liabilities with Covenants
- Amendments to MFRS 107 and MFRS 7: Supplier Finance Arrangements

The adoption of the above pronouncements did not have any material impact to the condensed consolidated interim financial report of the Group.

(b) The Group has not applied in advance the following accounting standard(s) and/or interpretation(s) (including the consequential amendments, if any) that have been issued by the Malaysian Accounting Standards Board (MASB) but are not yet effective for the current financial period:-

Effective for financial periods beginning on or after 1 January 2025

Amendments to MFRS 121: Lack of Exchangeability

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

A2. Significant accounting policies (cont'd)

Effective for financial periods beginning on or after 1 January 2026

Amendments to MFRS 9 and MFRS 7: Amendments to the Classification and Measurement of Financial Instruments

Annual Improvements to MFRS Accounting Standards—Volume 11

Effective for financial periods beginning on or after 1 January 2027

MFRS 18 Presentation and Disclosure in Financial Statements

MFRS 19 Subsidiaries without Public Accountability: Disclosures

Effective date of these Standards have been deferred, and yet to be announced

Amendments to MFRS 10 and MFRS 128: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture

A3. Auditors' report

The auditors issued an unqualified audit opinion on the audited consolidated financial statements for the financial year ended 30 June 2024.

A4. Seasonal or cyclical factors

The nature of the Group's business was not subject to any significant seasonal and cyclical factors.

A5. Unusual item affecting Assets, Liabilities, Equity, Net Income or Cash Flows

There were no material unusual items affecting assets, liabilities, equity, net income or cash flows during the current financial quarter under review.

A6. Material changes in accounting estimates

There were no material changes in accounting estimates that have a material effect in the current financial quarter.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

A7. Material events during the statement of financial position date

There were no material events during the current financial quarter under review that have not been reflected in the condensed consolidated interim financial report.

A8. Material events subsequent to the statement of financial position date

There were no material events subsequent to the end of the current financial quarter that have not been reflected in the condensed consolidated interim financial report.

A9. Material changes in the composition of the Group

There were no changes in the composition of the Group for the current financial quarter under review.

A10. Debt and equity securities

There were no other issuance, cancellations, repurchases, resale and repayments of debt and equity securities for the current financial quarter under review, except as disclosed in Note B7.

A11. Dividends paid

On 27 September 2024, the Company paid an interim single-tier dividend of 0.37 sen per ordinary share in respect of the financial year ended 30 June 2024 amounting to RM3.08 million.

There were no dividends paid during the current financial quarter under review.

A12. Operating segments

No geographical segment information is presented as the Group's revenue and profit or loss are confined within Malaysia.

A13. Valuations of property, plant and equipment

The Group does not adopt a revaluation policy on its property, plant and equipment. All property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)
(Incorporated in Malaysia)

A14. Contingencies

There were no contingent assets and contingent liabilities as at the date of this condensed consolidated interim financial report.

A15. Related party transactions

Identities of related parties

For the purposes of this condensed consolidated interim financial report, parties are considered to be related to the Group if the Group has the ability, directly or indirectly, to control or jointly control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the parties are subject to common control. Related parties may be individuals or other entities.

Related parties also include key management personnel defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Group either directly or indirectly and entity that provides key management personnel services to the Group. The key management personnel include all the Directors and certain members of senior management of the Group.

The Group has related party relationship with its Directors, associates, joint venture and key management personnel and entities within the same group of companies.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

A15. Related party transactions (cont'd)

Significant related party transactions

Significant related party transactions of the Group are as follows:

	← Unaudited →			
	Individual quarter ended 31 December		Cumulative quarter ended 31 December	
	2024	2023	2024	2023
	RM'000	RM'000	RM'000	RM'000
Transactions				
External consultancy fee contributed by directors	(82)	(104)	(162)	(219)
External consultancy fee contributed by other key management personnel	(73)	(60)	(129)	(136)
Anciliary services paid to an associate	5	-	5	-
Anciliary services paid to a joint venture	-	-	3	-
Consultant fee paid to an associate(s)	116	-	116	-
Consultant fee paid to a joint venture(s)	-	46	117	102
Hospital cost paid to an associate(s)	59	-	59	-
Hospital cost paid to a joint venture(s)	-	25	56	59
Rental income charged to an associate	(36)	-	(70)	-
Management fee charged to an associate(s)	(87)	-	(168)	-
Management fee charge to joint venture(s)	-	(3)	(6)	(6)
	<u>-</u>	<u>(3)</u>	<u>(6)</u>	<u>(6)</u>

A16. Fair value information

There was no gain or loss arising from fair value changes of the Group's financial liabilities for the current quarter and financial period under review.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

PART B - EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF ACE MARKET LISTING REQUIREMENT OF BURSA MALAYSIA SECURITIES BERHAD

B1. Review of financial performance

a) Review of the current financial quarter against preceding corresponding financial quarter

	← Unaudited →		
	Individual quarter		
	ended 31 December		
	2024	2023	Variance
	RM'000	RM'000	%
Revenue	20,177	16,054	25.68
Profit before taxation ("PBT")	<u>4,057</u>	<u>3,997</u>	1.50

The Group recorded revenue of RM20.18 million for the current financial quarter ended 31 December 2024, representing a increase of approximately 25.68% as compared to the preceding corresponding financial quarter ended 31 December 2023 of RM16.05 million. The increase is mainly due to patient volume and number of surgeries performed for the current quarter.

The Group's PBT increased by RM0.06 million or 1.50% for the current quarter mainly due to the increase in revenue but was offset by higher staff costs and accelerated depreciation of current building renovation.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

B1. Review of financial performance (cont'd)

b) Review of the current cumulative financial quarter against corresponding preceding cumulative financial quarter

	← Unaudited →		
	Cumulative quarter ended 31 December		
	2024	2023	Variance
	RM'000	RM'000	%
Revenue	42,466	33,658	26.17
PBT	<u>9,713</u>	<u>8,737</u>	11.17

The Group recorded revenue of RM42.47 million for the cumulative quarter ended 31 December 2024, representing a increase of RM8.81 million or 26.17% as compared to the corresponding preceding cumulative quarter ended 31 December 2023 of RM33.66 million. The increase in revenue was mainly due to higher patients volume, coupled with the increase in number of surgeries performed.

The Group's PBT increased by RM0.98 million or 11.17% for the current cumulative quarter mainly due to the increase in revenue but was offset by higher staff costs and accelerated depreciation of current building renovation.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)
(Incorporated in Malaysia)

B2. Variation of results against preceding quarter

	← Unaudited →		
	Individual quarter ended		
	December	September	
	2024	2024	Variance
	RM'000	RM'000	%
Revenue	20,177	22,289	(9.48)
PBT	<u>4,057</u>	<u>5,656</u>	(28.27)

The Group recorded revenue of RM20.18 million for the current quarter ended 31 December 2024, representing a decrease of RM2.11 million or 9.48% as compared to the preceding quarter ended 30 September 2024 of RM22.29 million. The decrease in revenue was mainly due to decrease in number of endoscopic procedures performed.

The Group's PBT decreased by RM1.60 million or approximately 28.27% from RM5.66 million in the immediate preceding quarter to RM4.06 million in the current financial quarter. The decrease was mainly due to the decline in revenue, coupled with by higher staff costs and accelerated depreciation of current building renovation.

B3. Commentary on prospects

Given the performance of the Group 6-month financial period ended 31 December 2024, the Board of Directors expect the Group's prospects for the financial year ending 30 June 2025 to be favourable.

B4. Profit forecast

Not applicable as the Group does not publish any profit forecast.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

B5. Income tax expense

Income tax expense comprises the following:

	← Unaudited →			
	Individual quarter ended 31 December		Cumulative quarter ended 31 December	
	2024	2023	2024	2023
	RM'000	RM'000	RM'000	RM'000
<i>Recognised in profit or loss</i>				
Current financial period				
Current tax expense	1,443	1,196	3,074	2,562
Deferred tax	(331)	(122)	(307)	(348)
	<u>1,112</u>	<u>1,074</u>	<u>2,767</u>	<u>2,214</u>
Effective tax rate	27.41%	26.87%	28.49%	25.34%

The effective tax rate for the current quarter and the cumulative quarter ended 31 December 2024 were 27.41% and 28.49% respectively, which were higher than the statutory tax rate mainly due to the non-deductible expenses incurred.

The effective tax rate for the current quarter and the cumulative quarter ended 31 December 2023 were 26.87% and 25.34% respectively, which were higher than the statutory tax rate mainly due to the non-deductible expenses incurred.

Income tax expense in the form of provision is recognised based on management's estimate.

B6. Status of corporate proposals announced

There are no other corporate proposals announced but not completed as at the date of this report.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

B7. Loans and borrowings

Particulars of the Group's loans and borrowings are as follows:

	Note	Unaudited As at 31 December 2024 RM'000	Audited As at 30 June 2024 RM'000
Non-current			
Term loans - secured		25,692	-
		<u>25,692</u>	<u>-</u>
Current			
Term loans - secured		-	-
		<u>-</u>	<u>-</u>

The above borrowings are denominated in Ringgit Malaysia.

B8. Lease liabilities

	Note	Unaudited As at 31 December 2024 RM'000	Audited As at 30 June 2024 RM'000
Non-current			
Lease liabilities	B8.1	4,220	5,665
		<u>4,220</u>	<u>5,665</u>
Current			
Lease liabilities	B8.1	2,730	2,478
		<u>2,730</u>	<u>2,478</u>

The above lease liabilities are denominated in Ringgit Malaysia.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)
(Incorporated in Malaysia)

B8. Lease liabilities (cont'd)

B8.1 Lease liabilities

Lease liabilities are payable as follows:

	Future minimum lease payments RM'000	Interest RM'000	Present value of minimum lease payments RM'000
Unaudited			
31.12.2024			
Less than one year	2,970	240	2,730
Between one to five years	4,357	137	4,220
Over 5 years	-	-	-
	<u>7,327</u>	<u>377</u>	<u>6,950</u>
Audited			
30.6.2024			
Less than one year	2,773	295	2,478
Between one to five years	5,908	243	5,665
Over 5 years	-	-	-
	<u>8,681</u>	<u>538</u>	<u>8,143</u>

B9. Material litigation

There are no material litigations as at the date of this report.

B10. Dividends

On 24 January 2025, the Company declared an interim single-tier dividend of RM0.006 per ordinary share in respect of the financial year ending 30 June 2025, to be paid on 28 February 2025 to shareholders of the Company whose names appear in the Record of Depositors on 13 February 2025.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

B11. Earnings per ordinary share

The calculation of earnings per ordinary share at 31 December 2024 and 2023, was based on the profit attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding calculated as follows:

	← Unaudited →			
	Individual quarter ended		Cumulative quarter ended	
	31 December 2024	2023	31 December 2024	2023
Profit for the financial period attributable to owners of the Company (RM'000)	2,945	2,923	6,946	6,523
Based on weighted average number of ordinary shares - basic ('000)	832,913 ⁽¹⁾	832,913 ⁽²⁾	832,913 ⁽¹⁾	832,909 ⁽²⁾
Effect of unexercised ESOS	-	450	-	1,529
Adjusted weighted average number of ordinary shares ('000)	832,913	833,363	832,913	834,438
Basic earnings per ordinary share (sen)	0.35	0.35	0.83	0.78
Diluted earnings per ordinary share (sen)	0.35	0.35	0.83	0.78

⁽¹⁾ Based on the weighted average number of issued share capital of 818,800,000 ordinary shares after the completion of the IPO, and with inclusion of number of ordinary shares from exercised ESOS and Special Issue shares.

⁽²⁾ Based on the weighted average number of issued share capital of 818,800,000 ordinary shares after the completion of the IPO, and with inclusion of number of ordinary shares from exercised ESOS and Special Issue shares.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

B12. Profit before taxation

	← Unaudited →			
	Individual quarter ended		Cumulative quarter ended	
	31 December		31 December	
	2024	2023	2024	2023
	RM'000	RM'000	RM'000	RM'000
Profit before taxation is arrived at after charging/ (crediting):-				
Depreciation:				
- plant and equipment	1,246	467	2,446	891
- right-of-use assets	337	326	673	652
Rent concessions	-	-	(17)	-
Plant and equipment written off	-	2	-	2
Directors' remuneration	1,857	1,985	3,685	3,985
Staff costs:				
- short-term employee benefits	4,890	4,054	9,527	8,366
- defined contribution benefits	539	439	1,041	925
- LTIP expenses	28	34	57	67
Interest expense:				
- lease liabilities	77	163	160	330
- unwinding of discount	8	7	15	15
- others	-	1	-	1
Total interest income on financial assets measured at amortised cost	(759)	(830)	(1,574)	(1,746)

The Group did not report any provision for and write off of inventories, gain or loss on disposal of quoted or unquoted investments or properties, foreign exchange gain or loss and gain or loss on derivatives for the financial period under review.

Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

B13. Utilisation of proceeds

The status of the utilisation of proceeds raised from the IPO of RM72.20 million and the variation of the use of proceeds is as follows:

<u>Details of utilisation</u>	<u>(A)</u>	<u>(B)</u>	<u>(C) = (A) - (B)</u>						
	Original intention for utilisation	Actual utilisation as at to date	Balance of proceeds as at to date	Variation	Balance of proceeds after variation	Actual utilisation as at to date	Balance of proceeds as at to date	Original timeframe for utilisation of proceeds	Revised timeframe for utilisation of proceeds
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000		
Expansion of existing medical centre	13,000	3,092	9,908	(9,908)	-	-	-	Within 36 months from the Listing Date	-
Establishing new medical centres	37,100	-	37,100	(18,550)	18,550	-	18,550	Within 36 months from the Listing Date	-
Acquisition of new stratified property forming part of a purpose-built private medical centre	-	-	-	36,258	36,258	(36,258)	-	-	Within 36 months from the unconditional date of the sale and purchase agreement
Working capital	17,404	4,153	13,251	(7,800)	5,451	-	5,451	Within 24 months from the Listing Date	Within 36 months from the Listing Date
Defraying the listing expenses	4,700	4,497	203 ⁽¹⁾	-	203 ⁽¹⁾	-	203	Within 1 month from the Listing Date	
Total	72,204	11,742	60,462	-	60,462	(36,258)	24,204		

Note:

⁽¹⁾ The balance proceeds from listing expenses of RM203,000 will be re-allocated for working capital purposes.